Rankings
▼
Calendar
RCUS Q2 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
RCUS
Arcus Biosciences, Inc.
$2B
Q2 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$27M
+185.4% YoY
Gross Profit
$27M
100.0% margin
Operating Income
-$69M
-255.6% margin
Net Income
-$67M
-248.1% margin
EPS (Diluted)
$-0.90
QoQ Revenue Growth
+50.0%
Cash Flow
Operating Cash Flow
-$65M
Free Cash Flow
-$72M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$729M
Stockholders' Equity
$747M
Cash & Equivalents
$273M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$27M
$9M
+185.4%
Gross Profit
$27M
$9M
+185.4%
Operating Income
-$69M
-$76M
+9.4%
Net Income
-$67M
-$76M
+11.8%
Revenue Segments
License and Development Services for All Gilead Programs
$17M
62%
Gilead Access Rights
$8M
31%
Taiho Access Rights
$2M
7%
← FY 2022
All Quarters
Q3 2022 →